IL9 and inflammatory bowel disease: As IL-12 and IL-23 might play distinct roles in this imbalance by stimulating ILC1 and ILC3 differentiation, respectively, we studied the effect of ustekinumab (which neutralizes the common p40 chain of IL-12 and IL-23) on ILC populations in blood and intestinal biopsies of IBD patients (20–22).